Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSL ( (AU:CSL) ) has provided an update.
CSL Limited has partnered with Dutch biotech firm VarmX to develop VMX-C001, a first-in-class treatment aimed at restoring blood coagulation in patients on FXa inhibitors who experience severe bleeding or require urgent surgery. This collaboration aligns with CSL’s strategy to expand its clinical and commercial pipeline through external partnerships. The U.S. FDA has granted Fast Track Designation to VMX-C001, highlighting its potential to meet a critical unmet medical need. CSL will fund the global Phase 3 trial and has secured an exclusive option to acquire VarmX, with commercial launch anticipated in 2029.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company specializing in hematology and bleeding disorders. The company focuses on developing innovative therapies to address unmet medical needs and has a strategic ambition to enhance patient impact through partnerships and investments in clinical-stage opportunities.
YTD Price Performance: -24.73%
Average Trading Volume: 1,050,983
Technical Sentiment Signal: Sell
Current Market Cap: A$100.8B
See more insights into CSL stock on TipRanks’ Stock Analysis page.